International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010

Summary

The main goal of this study is to improve the outcome of children and adolescents with standard risk (SR) first relapsed acute lymphoblastic leukemia. Furthermore, goal is to set up a large international study group platform allowing for optimization of standard treatment strategies and integration of new agents.

Conditions

• Acute Lymphoblastic Leukemia (ALL)

Interventions

DRUG

SR-A + Epratuzumab

DRUG

SR-B + Epratuzumab

Sponsors & Collaborators

• Australian & New Zealand Children's Haematology/Oncology Group

  collaborator OTHER

• St. Anna Kinderkrebsforschung (Co-Sponsor Austria)

  collaborator UNKNOWN

• European Organisation for Research and Treatment of Cancer - EORTC

  collaborator NETWORK

• University Hospital Motol (Co-Sponsor Czech Republic)

  collaborator UNKNOWN

• Copenhagen University Hospital (Rigshospitalet) (Co-Sponsor Copenhagen)

  collaborator UNKNOWN

• Turku University (Co-Sponsor Finland)

  collaborator UNKNOWN

• Centre Hospitalier Universitaire de Nice

  collaborator OTHER

• Our Lady's Chilrden's Hospital (Co-Sponsor Ireland)

  collaborator UNKNOWN

• Tel Aviv Sourasky Medical Centre (Co-Sponsor Israel)

  collaborator UNKNOWN

• Ospedale Pediatrico Bambino Gesù (Co-Sponsor Italy)

  collaborator UNKNOWN

• National Hospital Organization Nagoya Medical Center (Co-Sponsor Japan)

  collaborator UNKNOWN

• Prinses Máxima Centrum (Co-Sponsor Netherlands)

  collaborator UNKNOWN

• Oslo University Hospital (Co-Sponsor Oslo)

  collaborator UNKNOWN

• Medical University of Wroclaw (Co-Sponsor Poland)

  collaborator UNKNOWN

• Instituto Português de Oncologia de Lisboa (Co-Sponsor Lisboa)

  collaborator UNKNOWN

• Spanish Society of Pediatric Hematology and Oncology (SEHOP) (Co-Sponsor Spain)

  collaborator UNKNOWN

• University Children's Hospital, Zurich

  collaborator OTHER

• Central Manchester University (Co-Sponsor United Kingdom)

  collaborator UNKNOWN

• Charite University, Berlin, Germany

  lead OTHER

Principal Investigators

• Arend von Stackelberg, MD · University Hospital of Berlin - Charité

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

1 Day

Max Age

17 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2014-05-31

Primary Completion

2023-07-31

Completion

2023-07-31

Countries

• Australia
• Austria
• Belgium
• Czechia
• Denmark
• Finland
• France
• Germany
• Israel
• Italy
• Japan
• Netherlands
• Norway
• Poland
• Portugal
• Switzerland
• United Kingdom

Study Locations